Press Releases
Samsung Biologics recognized for business excellence in receiving the 2023 CDMO Leadership Awards for 10th consecutive year
Samsung Biologics has been selected as a recipient of the 2023 CDMO Leadership Awards presented by Outsourced Pharma and Life Science Leader.
Samsung Biologics received awards in all six performance categories: capabilities, compatibility, expertise, quality, reliability, and service. In particular, the company garnered further recognition as a Champion in capabilities, compatibility, quality, and reliability, reflecting the company’s commitment to operational excellence as a trusted end-to-end service provider.
“We are very honored to receive the CDMO Leadership Awards for 10 consecutive years, and for achieving Champion status in capabilities, compatibility, quality and reliability this year,” said John Rim, CEO and President of Samsung Biologics. “These awards reflect the trust clients have in our competitiveness. We will continue to meet client and partner expectations by providing high-quality biopharmaceuticals through our expanded capabilities in contract development and manufacturing.”
Samsung Biologics has demonstrated strong business agility with Plants 1, 2 and 3 under full utilization. The company plans to add new capabilities, including an antibody-drug conjugate facility at Plant 4, which is under partial operation and on track for full completion by mid-2023. Upon completion of the latest plant, Samsung Biologics will reaffirm its position as holding the largest biomanufacturing capacity at a single site with 604,000 liters to serve the needs of the clients.
“For over a decade, these awards have been the most meaningful for biopharma organizations striving to obtain optimal outcomes from their outsourcing activities. Our research arm, ISR Reports, which only surveys drug sponsors who have worked directly and recently with specific CDMOs, ensures the validity of these results. Our winners are your gold medalists of outsourcing.,” said Louis Garguilo, Chief Editor and Conference Chair at Outsourced Pharma.
The CDMO Leadership Awards, now in its 12th year, offers accurate and reliable customer feedback to provide support in choosing a reputable partner for development and manufacturing needs. For this year’s awards, 72 contract manufacturers were assessed by 23 performance metrics as well as their work on an outsourced project within the past 18 months.
Samsung Biologics has been selected as a recipient of the 2023 CDMO Leadership Awards presented by Outsourced Pharma and Life Science Leader.
Samsung Biologics received awards in all six performance categories: capabilities, compatibility, expertise, quality, reliability, and service. In particular, the company garnered further recognition as a Champion in capabilities, compatibility, quality, and reliability, reflecting the company’s commitment to operational excellence as a trusted end-to-end service provider.
“We are very honored to receive the CDMO Leadership Awards for 10 consecutive years, and for achieving Champion status in capabilities, compatibility, quality and reliability this year,” said John Rim, CEO and President of Samsung Biologics. “These awards reflect the trust clients have in our competitiveness. We will continue to meet client and partner expectations by providing high-quality biopharmaceuticals through our expanded capabilities in contract development and manufacturing.”
Samsung Biologics has demonstrated strong business agility with Plants 1, 2 and 3 under full utilization. The company plans to add new capabilities, including an antibody-drug conjugate facility at Plant 4, which is under partial operation and on track for full completion by mid-2023. Upon completion of the latest plant, Samsung Biologics will reaffirm its position as holding the largest biomanufacturing capacity at a single site with 604,000 liters to serve the needs of the clients.
“For over a decade, these awards have been the most meaningful for biopharma organizations striving to obtain optimal outcomes from their outsourcing activities. Our research arm, ISR Reports, which only surveys drug sponsors who have worked directly and recently with specific CDMOs, ensures the validity of these results. Our winners are your gold medalists of outsourcing.,” said Louis Garguilo, Chief Editor and Conference Chair at Outsourced Pharma.
The CDMO Leadership Awards, now in its 12th year, offers accurate and reliable customer feedback to provide support in choosing a reputable partner for development and manufacturing needs. For this year’s awards, 72 contract manufacturers were assessed by 23 performance metrics as well as their work on an outsourced project within the past 18 months.